keyword
MENU ▼
Read by QxMD icon Read
search

Palivizumab

keyword
https://www.readbyqxmd.com/read/28324595/recent-advances-in-developing-antiviral-therapies-for-respiratory-syncytial-virus
#1
REVIEW
Brian C Shook, Kai Lin
Respiratory syncytial virus (RSV) infection presents a significant health challenge in small children, the elderly and immunocompromised patients. There is still a high unmet medical need among patients with RSV infection, and no specific antiviral therapy is available. The only approved agents are palivizumab, which has to be given prophylactically, mainly in high-risk infants, and ribavirin, which is rarely used due to toxicity concerns and questionable benefits. Efforts to develop new antiviral agents have been hampered by the perceived need for high safety hurdles in pediatric patient populations use and the lack of well-characterized druggable targets...
April 2017: Topics in Current Chemistry (Journal)
https://www.readbyqxmd.com/read/28303835/trends-of-respiratory-syncytial-virus-sub-types-in-children-hospitalised-at-a-tertiary-care-centre-in-jaipur-during-2012-2014
#2
M Anjaneya Swamy, Bharti Malhotra, P V Janardhan Reddy, Jitendra Kumar Tiwari, Neeraj Kumar, Manohar Lal Gupta
Respiratory syncytial virus (RSV) causes high mortality and morbidity in infants. The study was planned to determine the trends of RSV sub-types in hospitalised children. Nasopharyngeal aspirate and throat swabs were collected from the hospitalised children up to 5 years of age. Viral nucleic acid was extracted using easyMAG automated extraction system, and real-time reverse transcription polymerase chain reaction was performed. Total positivity for RSV was found to be 25.40%, predominantly for RSV B (20.03%), followed by RSV A (2...
January 2017: Indian Journal of Medical Microbiology
https://www.readbyqxmd.com/read/28276287/benzimidazole-based-derivatives-as-privileged-scaffold-developed-for-the-treatment-of-the-rsv-infection-a-computational-study-exploring-the-potency-and-cytotoxicity-profiles
#3
Elena Cichero, Michele Tonelli, Federica Novelli, Bruno Tasso, Ilenia Delogu, Roberta Loddo, Olga Bruno, Paola Fossa
Respiratory syncytial virus (RSV) has been identified as a main cause of hospitalisation in infants and children. To date, the current therapeutic arsenal is limited to ribavirin and palivizumab with variable efficacy. In this work, starting from a number of in-house series of previously described anti-RSV agents based on the benzimidazole scaffold, with the aim at gaining a better understanding of the related chemical features involved in potency and safety profiles, we applied a computational study including two focussed comparative molecular fields analysis (CoMFA) and comparative molecular similarity indices analysis (CoMSIA)...
December 2017: Journal of Enzyme Inhibition and Medicinal Chemistry
https://www.readbyqxmd.com/read/28275185/broadly-reactive-anti-rsv-g-antibodies-from-exposed-individuals-effectively-inhibit-infection-of-primary-airway-epithelial-cells
#4
B Cortjens, E Yasuda, X Yu, K Wagner, Y B Claassen, A Q Bakker, J B M van Woensel, T Beaumont
Respiratory syncytial virus (RSV) causes severe respiratory disease in young children. Antibodies specific for the RSV prefusion F protein have guided RSV vaccine research and in human serum these antibodies attribute to >90% of the neutralization response, however detailed insight in the composition of the human B cell repertoire against RSV is still largely unknown. In order to study the B cell repertoire of 3 healthy donors for specificity against RSV, CD27(+) memory B cells were isolated and immortalized using BCL6 and Bcl-xL...
March 8, 2017: Journal of Virology
https://www.readbyqxmd.com/read/28273842/immunological-features-of-respiratory-syncytial-virus-caused-pneumonia-implications-for-vaccine-design
#5
REVIEW
Emma Rey-Jurado, Alexis M Kalergis
The human respiratory syncytial virus (hRSV) is the causative agent for high rates of hospitalizations due to viral bronchiolitis and pneumonia worldwide. Such a disease is characterized by an infection of epithelial cells of the distal airways that leads to inflammation and subsequently to respiratory failure. Upon infection, different pattern recognition receptors recognize the virus and trigger the innate immune response against the hRSV. Further, T cell immunity plays an important role for virus clearance...
March 4, 2017: International Journal of Molecular Sciences
https://www.readbyqxmd.com/read/28236796/cost-effectiveness-of-a-protocol-using-palivizumab-in-preterm-infants
#6
Yolanda Hernández-Gago, Marina Lombardero-Pin, Casilda Ortega de la Cruz, Pablo A Maciuniak, Alicia Díez Del Pino
OBJECTIVE: The main objective was to evaluate the cost-effectiveness of protocol use of palivizumab in premature established by consensus in our Hospital comparing it based on the recommendations of various Scientific Societies. As a secondary objective risk factors and severity of hospitalized patients attending the established protocol in our Hospital were analyzed. METHODS: The study period was 4 seasons with the expanded protocol (retrospective data) versus 2 with restricted or agreed protocol (prospective data)...
March 1, 2017: Farmacia Hospitalaria
https://www.readbyqxmd.com/read/28236418/one-year-observational-study-of-palivizumab-prophylaxis-on-infants-at-risk-for-respiratory-syncytial-virus-infection-in-latin-america
#7
Leandro Martin Castillo, Gabriela Bugarin, Juan Carlos Arias, Jairo Israel Barajas Rangel, Maria Elina Serra, Nestor Vain
OBJECTIVE: This study aims to describe real world palivizumab use and effectiveness in high-risk Latin American infants and young children. METHOD: Prospective, multicenter observational study with infants at risk for severe RSV infection who received palivizumab according to routine clinical practice. Subjects were followed for one year with monthly visits after the first dose of palivizumab. An infant was considered adherent if receiving all the expected injections or five or fewer injections within appropriate inter-dose intervals...
February 22, 2017: Jornal de Pediatria
https://www.readbyqxmd.com/read/28219614/palivizumab-prophylaxis-in-preterm-infants
#8
Paul Kiet Tang
No abstract text is available yet for this article.
February 14, 2017: Lancet Respiratory Medicine
https://www.readbyqxmd.com/read/28188494/palivizumab-exposure-and-the-risk-of-atopic-dermatitis-asthma-and-allergic-rhinoconjunctivitis-a-cross-national-population-based-cohort-study
#9
Ann Haerskjold, Lonny Stokholm, Marie Linder, Simon Francis Thomsen, Gunnar Bergman, Ingegärd Anveden Berglind, Helle Kieler, Henrik Ravn, Lone Graff Stensballe
BACKGROUND: Palivizumab is a humanized monoclonal antibody designed to provide passive immunity against respiratory syncytial virus. It is prescribed to children at high risk for severe infection with respiratory syncytial virus. However, little is known about the risk of the immune-mediated diseases atopic dermatitis, asthma, and allergic rhinoconjunctivitis after palivizumab exposure. AIM: Our objective was to investigate whether exposure to palivizumab was associated with atopic dermatitis, asthma, or allergic rhinoconjunctivitis in childhood...
April 2017: Paediatric Drugs
https://www.readbyqxmd.com/read/28187117/in-reply-statistical-power-to-detect-an-association-between-guideline-based-palivizumab-administration-and-hospitalizations-for-respiratory-syncytial-virus-infections
#10
Carlina J Grindeland, David D Leedahl
No abstract text is available yet for this article.
March 2017: Pediatric Infectious Disease Journal
https://www.readbyqxmd.com/read/28187116/statistical-power-to-detect-an-association-between-guideline-based-palivizumab-administration-and-hospitalizations-for-respiratory-syncytial-virus-infections
#11
Christopher S Ambrose
No abstract text is available yet for this article.
March 2017: Pediatric Infectious Disease Journal
https://www.readbyqxmd.com/read/28163166/respiratory-syncytial-virus-hospitalizations-in-infants-of-28-weeks-gestational-age-and-less-in-the-palivizumab-era
#12
Bernhard Resch, Beatrice Egger, Stefan Kurath-Koller, Berndt Urlesberger
OBJECTIVE: To obtain data on respiratory syncytial virus (RSV) associated hospitalization rates in preterm infants of 28 weeks gestational age and less in the era of palivizumab prophylaxis. METHODS: Retrospective single-center cohort study including all preterm infants up to 28 weeks+6days gestational age and born between 2004 and 2012 at a tertiary care university hospital. Data on RSV related hospitalizations over the first two years of life covering at least two RSV seasons (November-April) were analyzed...
February 2, 2017: International Journal of Infectious Diseases: IJID
https://www.readbyqxmd.com/read/28152315/palivizumab-prophylaxis-in-preterm-infants-and-subsequent-recurrent-wheezing-6-year-follow-up-study
#13
Hiroyuki Mochizuki, Satoshi Kusuda, Kenji Okada, Shigemi Yoshihara, Hiroyuki Furuya, Eric A F Simões
RATIONALE: RSV (respiratory syncytial virus) induces not only infantile recurrent wheezing but also potentially atopic asthma. OBJECTIVES: To test the effect of RSV infection, on development of subsequent atopic asthma, we evaluated whether palivizumab, an anti-RSV monoclonal antibody, by preventing severe RSV disease in the first year of life, could impact subsequent recurrent wheezing and atopic asthma, at 6 years of age. METHODS: During the 2007-2008 RSV season, the decision to administer palivizumab was made based on standard medical practice, and an observational prospective multicenter (n=52) case-control study in preterm infants with a gestational age between 33 and 35 weeks followed from 0 to 3 years (preceeding CREW study)...
February 2, 2017: American Journal of Respiratory and Critical Care Medicine
https://www.readbyqxmd.com/read/28134915/structural-basis-for-antibody-cross-neutralization-of-respiratory-syncytial-virus-and-human-metapneumovirus
#14
Xiaolin Wen, Jarrod J Mousa, John T Bates, Robert A Lamb, James E Crowe, Theodore S Jardetzky
Respiratory syncytial virus (RSV) and human metapneumovirus (HMPV) are two closely related viruses that cause bronchiolitis and pneumonia in infants and the elderly(1), with a significant health burden(2-6). There are no licensed vaccines or small-molecule antiviral treatments specific to these two viruses at present. A humanized murine monoclonal antibody (palivizumab) is approved to treat high-risk infants for RSV infection(7,8), but other treatments, as well as vaccines, for both viruses are still in development...
January 30, 2017: Nature Microbiology
https://www.readbyqxmd.com/read/28111638/rapid-profiling-of-rsv-antibody-repertoires-from-the-memory-b-cells-of-naturally-infected-adult-donors
#15
Morgan S A Gilman, Carlos A Castellanos, Man Chen, Joan O Ngwuta, Eileen Goodwin, Syed M Moin, Vicente Mas, José A Melero, Peter F Wright, Barney S Graham, Jason S McLellan, Laura M Walker
Respiratory syncytial virus (RSV) causes substantial morbidity and mortality in young children and the elderly. There are currently no licensed RSV vaccines, and passive prophylaxis with the monoclonal antibody palivizumab is restricted to high-risk infants in part due to its modest efficacy. Although it is widely agreed that an effective RSV vaccine will require the induction of a potent neutralizing antibody response against the RSV fusion (F) glycoprotein, little is known about the specificities and functional activities of RSV F-specific antibodies induced by natural infection...
December 16, 2016: Science Immunology
https://www.readbyqxmd.com/read/28105526/first-versus-second-year-respiratory-syncytial-virus-prophylaxis-in-chronic-lung-disease-2005-2015
#16
Daniel Y Wang, Abby Li, Bosco Paes, Ian Mitchell, Krista L Lanctôt
Children aged <2 years with chronic lung disease (CLD) have a 10-fold higher risk for respiratory syncytial virus-positive hospitalization (RSVH) compared to healthy term infants. Based on the updated position statements, we compared respiratory-related illness hospitalization (RIH) and RSVH risks in CLD children who received palivizumab during the first year (FY) versus second year (SY) of life in the Canadian Registry of Palivizumab (CARESS). Demographic data were collected at enrolment and RIH events recorded monthly from 2005 to 2015...
March 2017: European Journal of Pediatrics
https://www.readbyqxmd.com/read/28089687/stabilizing-effects-for-antibody-formulations-and-safety-profiles-of-cyclodextrin-polypseudorotaxane-hydrogels
#17
Taishi Higashi, Naoko Ohshita, Tatsunori Hirotsu, Yoshihito Yamashita, Keiichi Motoyama, Sawako Koyama, Ruriko Iibuchi, Takayuki Uchida, Shiuhei Mieda, Kenji Handa, Tomoaki Kimoto, Hidetoshi Arima
Antibodies often have poor physicochemical stability during storage and/or transport, which is a serious drawback for the development of antibody-based drugs. In this study, we prepared polypseudorotaxane (PPRX) hydrogels consisting of cyclodextrins (CyDs) and polyethylene glycol (PEG), and evaluated them as stabilizers for commercially available antibody-based drugs. α-CyD and γ-CyD formed PPRX hydrogels with PEG (MW 20,000 Da) in the presence of antibody-based drugs such as omalizumab, palivizumab, panitumumab, and ranibizumab...
January 12, 2017: Journal of Pharmaceutical Sciences
https://www.readbyqxmd.com/read/28078558/respiratory-syncytial-virus-associated-hospitalizations-in-preterm-infants-of-29-to-32%C3%A2-weeks-gestational-age-using-a-risk-score-tool-for-palivizumab-prophylaxis
#18
B Resch, V S Bramreiter, S Kurath-Koller, T Freidl, B Urlesberger
To evaluate the efficacy of palivizumab in infants of 29 to 32 weeks of gestational age (GA) based on a risk score tool developed for Austria. Retrospective single-center cohort study including all preterm infants of 29 (+0) to 32 (+6) weeks of GA born between 2004 and 2012 at a tertiary care university hospital. Data on RSV-related hospitalizations over the first 2 years of life were analyzed and compared between those having received palivizumab and those without. The study population was comprised of 789 of 816 screened infants, of whom 262 (33%) had received palivizumab and 527 (67%) had not...
January 11, 2017: European Journal of Clinical Microbiology & Infectious Diseases
https://www.readbyqxmd.com/read/28005688/respiratory-syncytial-virus-infection-associated-hospitalization-rates-in-infants-and-children-with-cystic-fibrosis
#19
Jakob Metz, Ernst Eber, Bernhard Resch
BACKGROUND: Infections with respiratory syncytial virus (RSV) are the leading cause for hospital admissions in infants and young children. The incidence of RSV-related hospitalizations in patients with cystic fibrosis (CF) is unclear. To date no effective treatment for RSV infections is available. Thus, prophylaxis with the monoclonal antibody palivizumab is an important option. METHODS: In a retrospective, single-center study at the Department of Paediatrics and Adolescent Medicine of the Medical University Graz, Austria, we analyzed all CF patients born between 1995 and 2012, who were admitted for respiratory problems between 1995 and 2014...
December 21, 2016: Pediatric Infectious Disease Journal
https://www.readbyqxmd.com/read/27989627/development-of-bioluminescence-imaging-of-respiratory-syncytial-virus-rsv-in-virus-infected-live-mice-and-its-use-for-evaluation-of-therapeutics-and-vaccines
#20
Sandra Fuentes, Diego Arenas, Martin M Moore, Hana Golding, Surender Khurana
Respiratory Syncytial virus (RSV) is one of the leading causes of pneumonia among infants with no human vaccine or efficient curative treatments. Efforts are underway to develop new RSV vaccines and therapeutics. There is a dire need for animal models for preclinical evaluation and selection of products against RSV. Herein, we developed a whole body bioluminescence imaging to follow replication of RSV A2 virus strain expressing firefly luciferase (RSVA2-line19-FFL) in live BALB/c mice that can be used as an extremely sensitive readout for studying effects of antiviral and vaccines in living mice...
December 15, 2016: Vaccine
keyword
keyword
44503
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"